ClinicalTrials.gov
ClinicalTrials.gov Menu

Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01185821
Recruitment Status : Completed
First Posted : August 20, 2010
Results First Posted : December 12, 2017
Last Update Posted : March 27, 2018
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

August 19, 2010
August 20, 2010
October 10, 2017
December 12, 2017
March 27, 2018
August 30, 2010
October 10, 2016   (Final data collection date for primary outcome measure)
  • Total Number of Adverse Events During Evaluation of Long Term Safety and Tolerability of BAF312A in Extension Study. [ Time Frame: Baseline up to approximately 5 years ]
    Refer to adverse events for complete listing of serious adverse events and other adverse events. Adverse events of interest were presented in separate tables. There were no reports of macular edema.
  • Number of Participants With Cardiac Conduction Abnormalities During the Titration Phase of the Study (Without Washout) [ Time Frame: Baseline Extension up to day 10 ]
    Number of patients with abnormal ECG conduction findings during dose-blinded titration at any visit post-dose, by type of abnormality and treatment (Extension Set). Number analyzed represent participants who had ECG results. Washout was defined as not being on treatment drug between Core and Extension for >7 days. Abbreviation: Con=conduction, IVCD=intraventricular conduction defect , WPW=Wolff-Parkinson-White syndrome
  • Number of Participants With Cardiac Conduction-IVCD Abnormality During the Titration Phase of the Study (With Washout) [ Time Frame: Baseline Extension up to day 10 ]
    Number of patients with abnormal ECG conduction findings during dose-blinded titration at any visit post-dose, by type of abnormality and treatment (Extension Set). Number analyzed represent participants who had ECG results. Washout was defined as not being on treatment drug between Core and Extension for >7 days. Abbreviations: washout = WO, Con=conduction
  • Number of Participants With Changes in Blood Pressure for Overall Extension Study. (Extension Analysis Set) [ Time Frame: Baseline Extension up to approximately 5 years ]
    Sitting blood pressure was measured in triplicate. The categories of notably low and high values and changes are presented for systolic (SBP) and diastolic (DBP). Multiple occurrences for a patient are counted as one occurrence in this table.
  • Number of Participants With Viral Infections of Interest Greater or Equal to 5% in Any Dose Group (Extension Set) [ Time Frame: Baseline Extension up to approximately 5 years ]

    Most infections were clinical diagnoses and were not confirmed by microbiology / virologic investigations. A patient with multiple occurrences of an infection for a preferred term is counted only once in each specific category.

    Events identified as infections by the Investigator and defined as an AE with onset on or after the first dose of Extension Study drug up to and including 30 days after the date of the last dose

  • Number of Participants With Dermatologic Alterations - Basal Cell Carcinoma (Extension Set) [ Time Frame: Baseline Extension up to approximately 5 years ]
Long-term safety and tolerability (emphasis on cardiovascular events, viral infections, macular edema and dermatologic alterations) [ Time Frame: up to 15 months ]
Complete list of historical versions of study NCT01185821 on ClinicalTrials.gov Archive Site
  • Number of Relapses in One Year - Annualized Relapse Rates for Overall Extension Study (ARR) (Extension Set) [ Time Frame: Baseline extension up to approximately 5 years ]

    Group level ARR (raw) is calculated as the total number of relapses for all the patients in the treatment group divided by the total number of days on study for all patients in the group and multiplied by 365.25 to obtain the annual rate.

    Model estimates are based on a negative binomial regression model, adjusted for treatment group, age, baseline EDSS, baseline number of Gd-enhanced T1 lesions and number of relapses in previous 2 years as covariates, with log(time on study in years) as the offset variable, using the log link.

  • Percentage of Participants Free of Magnetic Resonance Imaging (MRI) Identified Disease Activity at Any Scan During Extension Study (Extension Set) [ Time Frame: Baseline Extension up to approximately 5 years ]

    Free of MRI disease activity is defined as free of Gadolinium enhanced T1 lesions at any scan; free of new or enlarging T2 lesions at any scan: free of both gadolinium enhanced T1 lesions and new or enlarging T2 lesions at any scan. Number of patients analyzed = patients with at least one MRI scan during the specified time period. New lesions at a specific visit are assessed relative to the previous scheduled visit scan.

    No imputation of missing scans is performed. As a result missing scans can lead to an overestimation of the proportion of patients free of a specific MRI activity.

  • Percentage of Participants Free of Confirmed Disability Progression in Extension Study (Extension Set) [ Time Frame: Baseline Extension up to approximately 5 years ]
    Six-month disability progression was defined relative to extension baseline EDSS score: 1.5 point increase in patients with baseline EDSS score of 0, 1.0 increase in patients with baseline EDSS score of between 0.5 to 5.0, inclusive and 0.5 increase in patients with baseline EDSS score of ≥ 5.5. The criteria for 6-month disability progression included detection of onset of progression and confirmation of progression for a period of at least 6 months.
  • Long-term efficacy on clinical ground (relapse rate, disability progression) [ Time Frame: up to 15 months ]
  • Long-term efficacy on paraclinical ground (neuroradiological measures of neurodegeneration) [ Time Frame: up to 15 months ]
Not Provided
Not Provided
 
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
A Dose Blinded Extension Study to the CBAF312A2201 Study to Evaluate Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
This study consisted of a two year dose blinded phase during which patients received one of five doses of siponimod (10, 2, 1.25, 0.5 or 0.25mg) following which patients were switched to open label treatment with siponimod 2mg for approximately a further 3 years. It will provide data on long term safety, tolerability and efficacy of siponimod in the RRMS patient population
This study was prematurely discontinued after approximately 5 years. The decision to prematurely discontinue the study was not taken due to safety-related concerns, rather due to a decision to focus the development of siponimod in MS on a different population.
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
This extension study was originally set up as a 2 year dose-blinded extension study to maintain blinding of ongoing Core study. Study was later amended to include a subsequent Open-Label treatment phase after Core study was unblinded. During the Dose-Blinded phase of the extension study patients received the same dose from the Core study. Patients who received placebo in Period 1 during the Core Study were equally randomized to 1 of the 3 active doses of siponimod used during Period 1 (0.5, 2.0, or 10 mg) and patients who received placebo in Period 2 were equally randomized to 1 of the 2 active doses of siponimod used during Period 2 (0.25 mg or 1.25 mg).
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Masking continued during the double blind period of extension only.
Primary Purpose: Treatment
Relapsing Remitting Multiple Sclerosis
Drug: BAF312
BAF312 was supplied in film-coated tablets in strengths of 5, 4 ,2, 1, .5 and .25 mg. The actual doses taken were 10, 2, 1.25, .5 and .25 mg taken orally once a day.
Other Name: siponimod
  • Experimental: BAF312 10 mg/2 mg
    10 mg dose in Double Blind Phase and 2 mg in Open Label Phase
    Intervention: Drug: BAF312
  • Experimental: BAF312 2 mg/2 mg
    2 mg dose in Double Blind Phase and 2 mg in Open Label Phase
    Intervention: Drug: BAF312
  • Experimental: BAF312 1.25 mg/2 mg
    1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
    Intervention: Drug: BAF312
  • Experimental: BAF312 .5 mg/2 mg
    .5 mg dose in Double Blind Phase and 2 mg in Open Label Phase
    Intervention: Drug: BAF312
  • Experimental: BAF312 .25 mg/2 mg
    .25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
    Intervention: Drug: BAF312
Kappos L, Li DK, Stüve O, Hartung HP, Freedman MS, Hemmer B, Rieckmann P, Montalban X, Ziemssen T, Hunter B, Arnould S, Wallström E, Selmaj K. Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study. JAMA Neurol. 2016 Sep 1;73(9):1089-98. doi: 10.1001/jamaneurol.2016.1451.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
185
250
October 10, 2016
October 10, 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients completed the core study BAF312A2201
  • Written informed consent provided before any assessment of the extension study
  • Female patients at risk of becoming pregnant must have a negative pregnancy test and use simultaneously two forms of effective contraception

Exclusion Criteria:

  • Newly diagnosed systemic disease other than MS (which may require immunosuppressive treatment)
  • Malignancies, diabetes, significant cardiovascular and pulmonary diseases and conditions
  • Active infections
Sexes Eligible for Study: All
18 Years to 56 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Canada,   Finland,   Germany,   Hungary,   Italy,   Norway,   Poland,   Russian Federation,   Spain,   Switzerland,   Turkey,   United States
 
 
NCT01185821
CBAF312A2201E1
2009-014392-51 ( EudraCT Number )
Yes
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Not Provided
Novartis ( Novartis Pharmaceuticals )
Novartis Pharmaceuticals
Not Provided
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Novartis
February 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP